Dynamic Changes in Serum Bicarbonate During Neoadjuvant Chemotherapy Are Associated with Pathological Complete Response in Patients with Breast Cancer: A Retrospective Cohort Study

Breast cancer remains one of the most common and serious health challenges facing women worldwide. For many patients with locally advanced disease, doctors begin treatment with chemotherapy before surgery, a strategy known as neoadjuvant chemotherapy. The goal is to shrink the tumor and kill cancer cells throughout the body, hoping that by the time surgery occurs, no trace of the cancer remains. This complete disappearance of the tumor is called a pathological complete response, and it is a powerful sign that a patient will likely have better long-term survival. However, because doctors can only confirm this result after the tumor is removed, they lack a simple way to know during the treatment whether it is working. Meanwhile, scientists have long understood that cancer cells create a unique environment. As these cells grow rapidly, they consume energy in a way that produces acid, making the area around the tumor much more acidic than healthy tissue. This acidity can act like a shield, helping the cancer resist drugs and evade the immune system. Researchers have wondered if measuring the body's natural ability to neutralize this acid could provide a clue about how well the treatment is performing.

A team of researchers at the First Affiliated Hospital of Chongqing Medical University in China set out to investigate this idea by looking at a specific chemical in the blood called bicarbonate. Bicarbonate acts as a buffer, a substance that helps keep the body's acid levels balanced, much like a thermostat regulates temperature. The scientists wanted to see if changes in the amount of bicarbonate in a patient's blood during chemotherapy could predict whether the treatment would successfully eliminate the cancer. They analyzed data from 883 women who had been diagnosed with breast cancer and received chemotherapy between 2012 and 2020. For each patient, the team compared the level of bicarbonate in their blood before the first dose of chemotherapy with the level after the treatment was finished but before surgery.

The results revealed a clear pattern. While the starting levels of bicarbonate were similar for all patients, those who achieved a complete response showed a distinct change during their treatment. Their blood bicarbonate levels rose significantly more than those of patients whose cancer did not fully disappear. Specifically, the women who achieved a complete response saw their bicarbonate levels increase by an average of 1.60 millimoles per liter, compared to an increase of only 0.65 millimoles per liter for those who did not. Furthermore, the final levels of bicarbonate in the blood were higher in the successful group. The researchers used advanced statistical methods to ensure these findings were not simply due to other factors like age, body size, or the specific type of breast cancer a patient had. Even after accounting for these variables, the increase in bicarbonate remained a strong, independent predictor of a successful outcome.

The study suggests that the body's metabolic response to chemotherapy is linked to the treatment's effectiveness. When chemotherapy works well, it reduces the tumor burden, which may lower the amount of acid the cancer cells are producing. This reduction in acid load allows the body's natural buffering system to raise the bicarbonate levels in the blood. Conversely, if the cancer is resistant and continues to produce acid, the bicarbonate levels may not rise as much. The researchers found that this relationship held true across different subgroups of patients, including those with different hormone receptor statuses and varying levels of other blood markers. They also observed that the relationship was steady and linear, meaning that the greater the rise in bicarbonate, the higher the likelihood of a complete response.

Despite these promising findings, the authors are careful to note that their study was retrospective, meaning they looked back at existing records rather than following patients forward in time. This approach means they can identify a strong association but cannot prove that the change in bicarbonate directly causes the cancer to disappear. It is possible that the rise in bicarbonate is simply a side effect of the cancer shrinking, rather than a driver of the cure. Additionally, the study did not include detailed information on a specific type of breast cancer marker for all patients due to the long time span of the data collection, which could have influenced the results. The researchers also excluded patients with kidney problems, as the kidneys play a major role in managing acid levels, ensuring that their findings reflected the cancer treatment rather than organ dysfunction.

This work offers a new perspective on how we might monitor cancer treatment. Currently, doctors must wait until after surgery to know if chemotherapy worked. If future studies can confirm these results, a simple blood test measuring bicarbonate levels during treatment could provide an early signal of success or failure. This would be a significant step forward, as it relies on a test that is already routine, inexpensive, and widely available in hospitals. The findings connect the dots between the acidic nature of tumors and the body's systemic response, suggesting that the battle against cancer leaves a measurable trace in the blood. While more research is needed to validate these results in different populations and to understand the exact biological mechanisms at play, the study provides a compelling reason to watch how the body's chemistry changes as it fights the disease.